Frequency Therapeutics, Inc. (FREQ)

Market Cap	63.12M
Revenue (ttm)	n/a
Net Income (ttm)	-91.33M
Shares Out	35.26M
EPS (ttm)	-2.54
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	57,025
Open	1.82
Previous Close	1.90
Day's Range	1.79 - 1.89
52-Week Range	1.00 - 7.88
Beta	0.74
Analysts	Buy
Price Target	8.16 (+355.9%)
Earnings Date	Nov 14, 2022

About FREQ

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, i...

• Industry: Biotechnology
• IPO Date: Oct 3, 2019
• Employees: 72
• Stock Exchange: NASDAQ
• Ticker Symbol: FREQ

Full Company Profile

Financial Performance

In 2021, FREQ's revenue was $14.07 million, a decrease of -61.96% compared to the previous year's $36.98 million. Losses were -$84.69 million, 219.4% more than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for FREQ stock is "Buy." The 12-month stock price forecast is 8.16, which is an increase of 355.87% from the latest price.

Price Target

$8.16

(355.87% upside)

Analyst Consensus: Buy

Stock Forecasts